法维拉韦与 COVID-19：简化总结。
Favipiravir and COVID-19: A Simplified Summary.
机构信息
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran.
Department of Pediatrics, Faculty of Medicine, Motahari Hospital, Urmia University of Medical Sciences, Urmia, Iran.
出版信息
Drug Res (Stuttg). 2021 Mar;71(3):166-170. doi: 10.1055/a-1296-7935. Epub 2020 Nov 11.
Abstract
A recent outbreak of coronavirus disease 2019 (COVID-19) caused by the novel coronavirus designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in Wuhan, China, at the end of 2019 and then spread rapidly all over the world. However, there are no specific antiviral therapies for COVID-19, using the agents which approved or in development for other viral infections is one of the potentially quickest ways to find treatment for this new viral infection. Favipiravir is an effective agent that acts as a nucleotide analog that selectively inhibits the viral RNA dependent RNA polymerase or causes lethal mutagenesis upon incorporation into the virus RNA. In view of recent studies and discussion on favipiravir, in this mini review we aimed to summarize the clinical trials studying the efficacy and safety of favipiravir in patients with COVID-19.
摘要
2019 年末，新型冠状病毒（SARS-CoV-2）引发的 2019 冠状病毒病（COVID-19）疫情在中国武汉暴发，随后迅速在全球蔓延。然而，目前针对 COVID-19 尚无特效抗病毒疗法，使用已批准或正在开发用于其他病毒感染的药物是寻找这种新型病毒感染治疗方法的最快途径之一。法匹拉韦是一种有效的核苷酸类似物药物，可选择性抑制病毒 RNA 依赖性 RNA 聚合酶，或在掺入病毒 RNA 时导致致命的诱变。鉴于最近关于法匹拉韦的研究和讨论，在这篇迷你综述中，我们旨在总结研究法匹拉韦治疗 COVID-19 患者的疗效和安全性的临床试验。
相似文献
1
Favipiravir and COVID-19: A Simplified Summary.法维拉韦与 COVID-19：简化总结。
Drug Res (Stuttg). 2021 Mar;71(3):166-170. doi: 10.1055/a-1296-7935. Epub 2020 Nov 11.
2
Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.快速且允许的病毒 RNA 聚合酶复合物使法匹拉韦迅速掺入，导致 SARS-CoV-2 致命突变。
Nat Commun. 2020 Sep 17;11(1):4682. doi: 10.1038/s41467-020-18463-z.
3
The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.新型冠状病毒病患者核酸检测由阴转阳的机制及临床转归和法匹拉韦的疗效：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 5;21(1):488. doi: 10.1186/s13063-020-04430-y.
4
A review on favipiravir: the properties, function, and usefulness to treat COVID-19.关于法匹拉韦的综述：性质、功能及在治疗 COVID-19 中的用途。
Expert Rev Anti Infect Ther. 2021 Aug;19(8):1029-1037. doi: 10.1080/14787210.2021.1866545. Epub 2020 Dec 29.
5
Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2.关于法匹拉韦重新用于对抗新型冠状病毒的系统评价。
Mymensingh Med J. 2020 Jul;29(3):747-754.
6
A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.一项评估法匹拉韦和羟氯喹联合治疗中重度 COVID-19 住院成人的疗效和安全性的随机对照研究：研究方案的结构化总结。
Trials. 2020 Oct 31;21(1):904. doi: 10.1186/s13063-020-04825-x.
7
Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences.COVID-19 的抗病毒治疗：基于过去抗病毒和法匹拉韦经验的最佳策略推导。
Pharmacol Ther. 2022 Jul;235:108121. doi: 10.1016/j.pharmthera.2022.108121. Epub 2022 Feb 1.
8
Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.COVID-19 门诊患者的早期抗病毒治疗（FLARE）：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Mar 8;22(1):193. doi: 10.1186/s13063-021-05139-2.
9
Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis.法维拉韦与其他抗病毒药物或 COVID-19 治疗标准药物的比较：一项快速系统评价和荟萃分析。
Virol J. 2020 Sep 24;17(1):141. doi: 10.1186/s12985-020-01412-z.
10
Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir.接受法匹拉韦治疗的 COVID-19 患者鼻咽 SARS-CoV-2 病毒载量反应。
Jpn J Infect Dis. 2021 Sep 22;74(5):416-420. doi: 10.7883/yoken.JJID.2020.827. Epub 2021 Jan 29.
引用本文的文献
1
The Ability of Combined Flavonol and Trihydroxyorganic Acid to Suppress SARS-CoV-2 Reproduction.黄酮醇与三羟基有机酸联合抑制新型冠状病毒复制的能力
Viruses. 2024 Dec 30;17(1):37. doi: 10.3390/v17010037.
2
Favipiravir pharmacokinetics in Thai adults with mild COVID-19: A sub-study of interpatient variability and ethnic differences in exposure.法维拉韦在泰国轻症 COVID-19 成人患者中的药代动力学：暴露的患者间变异性和种族差异的亚研究。
Pharmacol Res Perspect. 2024 Dec;12(6):e1233. doi: 10.1002/prp2.1233.
3
Plausible mechanism of drug resistance and side-effects of COVID-19 therapeutics: a bottleneck for its eradication.新冠病毒治疗药物耐药性和副作用的可能机制：其根除的瓶颈。
Daru. 2024 Dec;32(2):801-823. doi: 10.1007/s40199-024-00524-z. Epub 2024 Jul 19.
4
Cyanobacterial and microalgae polymers: antiviral activity and applications.蓝藻和微藻聚合物：抗病毒活性与应用
Braz J Microbiol. 2024 Dec;55(4):3287-3301. doi: 10.1007/s42770-024-01452-5. Epub 2024 Jul 15.
5
A solvent-free HPLC method for the simultaneous determination of Favipiravir and its hydrolytic degradation product.一种无溶剂高效液相色谱法，用于同时测定法维拉韦及其水解降解产物。
Sci Rep. 2023 Oct 28;13(1):18512. doi: 10.1038/s41598-023-45618-x.
6
Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2.重新利用临床可用药物和疗法针对致病靶点来对抗新型冠状病毒。
MedComm (2020). 2023 May 14;4(3):e254. doi: 10.1002/mco2.254. eCollection 2023 Jun.
7
Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals.老年新冠患者独立合并症组的概况显示，与标准治疗及低剂量羟氯喹相比，抗病毒药物的致死率较低。
J Multidiscip Healthc. 2023 May 1;16:1215-1229. doi: 10.2147/JMDH.S403700. eCollection 2023.
8
Evaluation of the effect of favipiravir on patients with COVID-19.法匹拉韦对新型冠状病毒肺炎患者的疗效评估。
J Family Med Prim Care. 2023 Feb;12(2):242-245. doi: 10.4103/jfmpc.jfmpc_1058_22. Epub 2023 Feb 28.
9
Liver Injury in Favipiravir-Treated COVID-19 Patients: Retrospective Single-Center Cohort Study.法匹拉韦治疗的新冠肺炎患者的肝损伤：回顾性单中心队列研究
Trop Med Infect Dis. 2023 Feb 20;8(2):129. doi: 10.3390/tropicalmed8020129.
10
Plant-derived Ren's oligopeptide has antiviral effects on influenza virus and SARS-CoV-2.植物源任氏寡肽对流感病毒和新型冠状病毒具有抗病毒作用。
Front Vet Sci. 2023 Feb 2;9:1090372. doi: 10.3389/fvets.2022.1090372. eCollection 2022.
本文引用的文献
1
Discovering drugs to treat coronavirus disease 2019 (COVID-19).发现治疗2019冠状病毒病（COVID-19）的药物。
Drug Discov Ther. 2020;14(1):58-60. doi: 10.5582/ddt.2020.01012.
2
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).2019新型冠状病毒（2019-nCoV）的治疗选择。
Nat Rev Drug Discov. 2020 Mar;19(3):149-150. doi: 10.1038/d41573-020-00016-0.
3
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections.法匹拉韦，一种针对危及生命的 RNA 病毒感染的抗流感药物。
Pharmacol Ther. 2020 May;209:107512. doi: 10.1016/j.pharmthera.2020.107512. Epub 2020 Feb 22.
4
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）和 2019 年冠状病毒病（COVID-19）：疫情和挑战。
Int J Antimicrob Agents. 2020 Mar;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924. Epub 2020 Feb 17.
5
Defining the Epidemiology of Covid-19 - Studies Needed.定义新冠病毒病的流行病学——所需的研究。
N Engl J Med. 2020 Mar 26;382(13):1194-1196. doi: 10.1056/NEJMp2002125. Epub 2020 Feb 19.
6
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
7
Favipiravir as a potential countermeasure against neglected and emerging RNA viruses.非那韦作为一种针对被忽视和新兴 RNA 病毒的潜在对策。
Antiviral Res. 2018 May;153:85-94. doi: 10.1016/j.antiviral.2018.03.003. Epub 2018 Mar 7.
8
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.法匹拉韦（T-705），一种病毒RNA聚合酶的广谱抑制剂。
Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-463. doi: 10.2183/pjab.93.027.
9
Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis.T-705（法匹拉韦）和利巴韦林对流感病毒复制及病毒RNA合成的不同作用
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6679-6691. doi: 10.1128/AAC.01156-16. Print 2016 Nov.
10
The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.广谱抗病毒药物法匹拉韦可在疾病发作后保护豚鼠免受致死性拉沙病毒感染。
Sci Rep. 2015 Oct 12;5:14775. doi: 10.1038/srep14775.
Zotero 插件